resTORbio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. It focuses on the mechanistic target of rapamycin (mTOR) pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1 (TORC1). Its initial focus is on the development of RTB101, an orally administered, small molecule, potent TORC1 inhibitor, alone and in combination with other mTOR inhibitors, such as everolimus. Its product pipeline includes the TORC1 program that includes the development of RTB101 for various indications. The indications include respiratory tract infections, heart failure with preserved ejection fraction, autophagy related neurodegenerative diseases and other indications. The Company is developing RTB101 in a Phase II b clinical trial.
Market Cap:48.8M; Shares Outstanding:36.4M; Short Interest: 4.74%; Q3 2019(9/30/19): Cash 117M. Loss 24.45M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 60，no change
Shares hold: 23439k shares. no change
shares% hold: 64.32%，no change